8 stories mentioning CAHUpdated 10d ago
Every FINWIRES story that references CAH, newest first.
Cardinal Health (CAH) has an average rating of buy and mean price target of $246.93, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lower our 12-month price target to $225 from $260, 19.3x our FY 27 EPS estimate (up $0.24 to $11.66; FY 26 estimate up to $10.75 from $10.28), a premium to CAH's one- and three-year historical forward averages of 17.2x and 14.7x, respectively, to reflect our favorable outlook for pharmaceutical distributors.
Cardinal Health (CAH) has an average rating of overweight and mean price target of $249.07, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $193.78, Change: $+0.90, Percent Change: +0.47%
Cardinal Health (CAH) has an average rating of overweight and mean price target of $249.07, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $193.83, Change: $+0.95, Percent Change: +0.49%
Cardinal Health (CAH) has an average rating of overweight and mean price target of $249.07, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $193.83, Change: $+0.95, Percent Change: +0.49%
Cardinal Health (CAH) has an average rating of overweight and mean price target of $249.07, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $194.04, Change: $+1.16, Percent Change: +0.60%
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:Cardinal Health delivered its 15th consecutive quarterly earnings beat in Q3 FY 26, with adjusted EPS of $3.17 rising 35% Y/Y and beating consensus by $0.38. Revenue increased 11% Y/Y to $60.9B, missing consensus by $1.3B. The Pharmaceutical and Specialty Solutions segment drove strong performance, with 11% Y/Y revenue growth to $56.1B and margin expansion of 9 bps to 1.40%. Meanwhile, the Other segment surged 31% Y/Y with 21 bps margin expansion to 10.49%, offsetting GMPD segment headwinds where profit declined 36% due to adverse tariff impacts. CAH raised its adjusted EPS guidance by 4.9% at the midpoint, representing 30.5% growth vs. FY 25, while maintaining its GMPD segment sales and profit expectations despite ongoing challenges. We believe robust FCF generation remains a key strength. CAH raised its FY 26 FCF guidance to $3.5B from $3.25B previously, supporting continued capital returns through the additional $250M share repurchase completed during the quarter.
Cardinal Health (CAH) has an average rating of overweight and mean price target of $250.93, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)
